Sanofi - Company Profile
Powered by
All the data and insights you need on Sanofi in one report.
$295
- Save hours of research time and resources with
our up-to-date Sanofi Strategy Report
- Understand Sanofi position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreView up-to-date information on Sanofi patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
EP4058439A1 | Application | 5-GLIEDRIGE HETEROARYLAMINOSULFONAMIDE ZUR BEHANDLUNG VON DURCH MANGELNDE CFTR AKTIVITÄT VERMITTELTEN ERKRANKUNGEN | C07D277/52; C07D417/04; C07D417/12; C07D417/14; C07F9/6539 | September 21, 2022 |
EP4058106A1 | Application | ARZNEIMITTELABGABEVORRICHTUNG ZUR VERRINGERUNG VON DOSISMESSFEHLERN | A61M2005/2488; A61M2205/50; A61M2205/581; A61M2205/8212; A61M5/31551; A61M5/31553; A61M5/31568 | September 21, 2022 |
EP2413995B1 | Grant | DOSISKNOPF FÜR EINE ARZNEIMITTELABGABEVORRICHTUNG UND VERFAHREN ZUR HERSTELLUNG EINES DOSISKNOPFES | A61M2205/582; A61M2205/584; A61M2205/6036; A61M2205/6081; A61M37/00; A61M5/003; A61M5/20; Y10T409/303752; Y10T82/10; Y10T82/16016 | September 21, 2022 |
EP4058434A1 | Application | 6-GLIEDRIGE HETEROARYLAMINOSULFONAMIDE ZUM BEHANDELN VON KRANKHEITEN UND ZUSTÄNDEN, DIE DURCH MANGELNDE CFTR-AKTIVITÄT VERMITTELT WERDEN | A61K31/4418; A61K31/495; A61K31/496; A61K31/505; A61P11/00; A61P43/00; C07D213/75; C07D239/42; C07D239/69; C07D241/22; C07D401/12; C07D403/04; C07D403/12 | September 21, 2022 |
EP4058150A2 | Application | BIPARATOPISCHE CD73-ANTIKÖRPER | A61K2039/505; A61P35/00; C07K16/2896; C07K2317/31; C07K2317/32; C07K2317/522; C07K2317/55; C07K2317/56; C07K2317/76; C07K2317/94 | September 21, 2022 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer